78 related articles for article (PubMed ID: 2910492)
21. Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin.
Peters U; Preisler-Adams S; Lanvers-Kaminsky C; Jürgens H; Lamprecht-Dinnesen A
Anticancer Res; 2003; 23(2B):1249-55. PubMed ID: 12820379
[TBL] [Abstract][Full Text] [Related]
22. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
23. Auditory steady-state responses to bone conduction stimuli in children with hearing loss.
Swanepoel de W; Ebrahim S; Friedland P; Swanepoel A; Pottas L
Int J Pediatr Otorhinolaryngol; 2008 Dec; 72(12):1861-71. PubMed ID: 18963045
[TBL] [Abstract][Full Text] [Related]
24. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.
Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156
[TBL] [Abstract][Full Text] [Related]
25. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Gasparini M; Rouesse J; van Oosterom A; Wagener T; Somers R; Russel JA; Voûte PA; Bramwell V; Thomas D; Sylvester R
Cancer Treat Rep; 1985 Feb; 69(2):211-3. PubMed ID: 3855699
[TBL] [Abstract][Full Text] [Related]
27. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
Stöhr W; Langer T; Kremers A; Bielack S; Lamprecht-Dinnesen A; Frey E; Beck JD;
Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.
Stewart DJ; Wallace S; Feun L; Leavens M; Young SE; Handel S; Mavligit G; Benjamin RS
Cancer Res; 1982 May; 42(5):2059-62. PubMed ID: 7199971
[TBL] [Abstract][Full Text] [Related]
30. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
[TBL] [Abstract][Full Text] [Related]
31. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
Lokich JJ
Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073
[TBL] [Abstract][Full Text] [Related]
33. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
34. [Combination chemotherapy including cis-platinum in Ewing's sarcoma].
Matsumoto S; Kawaguchi N; Amino K; Manabe J; Furuya K; Isobe Y
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1913-6. PubMed ID: 3592719
[TBL] [Abstract][Full Text] [Related]
35. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
36. Patterns of hearing loss resulting from cis-platinum therapy.
Blakley BW; Myers SF
Otolaryngol Head Neck Surg; 1993 Sep; 109(3 Pt 1):385-91. PubMed ID: 8414553
[TBL] [Abstract][Full Text] [Related]
37. [Effect of high and low doses of methotrexate (MTX) on bone mass in subjects treated for osteosarcoma of the limbs].
Ripamonti C; Avella M; Gnudi S; Figus E
Minerva Med; 1993 Mar; 84(3):131-4. PubMed ID: 8492965
[TBL] [Abstract][Full Text] [Related]
38. [Use of prolonged intravenous infusions of cisplatin in patients with malignant neoplasms].
Tiuliadin SA
Vopr Onkol; 1983; 29(12):40-4. PubMed ID: 6582683
[TBL] [Abstract][Full Text] [Related]
39. [The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum].
Takahashi M; Katagiri H; Sato K; Sugiura H; Yamamura S; Fukaya N; Nakanishi K
Gan To Kagaku Ryoho; 1994 Mar; 21(4):459-64. PubMed ID: 8129386
[TBL] [Abstract][Full Text] [Related]
40. Preoperative administration of high-dose methotrexate for osteosarcoma.
Chan KW; Knowling MA; Duncan CP; Morton KS
Can J Surg; 1984 May; 27(3):305-7, 309. PubMed ID: 6586272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
